KRAS and pancreatic neoplasm: A study of KRAS G12R-mutant pancreatic cancer patients treated with selumetinib (KOSELUGOTM; ARRY-142886, an oral MEK1/2 inhibitor) showed a median PFS of 3.0 months and a median OS of 9 months.